Clinical Report: Exploring the Role of Neurofilament Light Chain in Spinal Muscular Atrophy

Overview

This study evaluates neurofilament light chain (NfL) levels in individuals with spinal muscular atrophy (SMA) and their correlation with disease characteristics.

Background

Spinal muscular atrophy (SMA) is a neurodegenerative condition that has seen significant advancements in diagnosis and treatment. Identifying biomarkers like neurofilament light chain (NfL) is important for monitoring disease progression.

Data Highlights

No numerical or trial data were provided in the source material.

Key Findings

• NfL levels are significantly higher in children with SMA compared to typically developing peers.
• NfL correlates with disease severity in SMA.
• Data on NfL in newborns with SMA is limited, necessitating further research in this population.
• High NfL levels are observed in individuals with a 2 SMN2 copy genotype, while variability exists in those with more than 2 copies.
• The study aims to evaluate pretreatment NfL levels and longitudinal changes in individuals not receiving immediate treatment.

Clinical Implications

Clinicians should consider NfL as a potential biomarker for monitoring disease activity and treatment response in SMA. Further research is needed to establish its utility in neonatal populations and across varying genotypes.

Conclusion

Further studies are needed to validate the role of NfL as a biomarker in diverse patient cohorts.

Related Resources & Content

1. Frontiers in Neurology, 2026 -- Neurofilament light chain reflects motor impairment in myotonic dystrophy type 1
2. Brain, 2023 -- Decoding inflammatory pathways in spinal muscular atrophy: implications for next-generation therapies
3. Brain, 2023 -- Extending the role of neurofilament light in multiple sclerosis beyond measuring irreversible neurodegeneration
4. Nature Reviews Neurology, 2026 -- Ten years of disease-modifying therapy in spinal muscular atrophy: lessons learned and future directions
5. PMC, 2024 -- Spinal Muscular Atrophy Update in Best Practices: Recommendations for Diagnosis Considerations
6. Brain — Variations in Factors Contributing to Mild and Severe Spinal Muscular Atrophy
7. NICE Guidance on Nusinersen and Risdiplam for Treating Spinal Muscular Atrophy
8. Ten years of disease-modifying therapy in spinal muscular atrophy: lessons learned and future directions | Nature Reviews Neurology
9. Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial
10. Efficacy and safety of risdiplam in patients with type 1 spinal muscular atrophy: a 3-year open-label extension of the two-part, phase 2 FIREFISH trial - ScienceDirect
11. Spinal Muscular Atrophy Update in Best Practices: Recommendations for Diagnosis Considerations - PMC
12. High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial | Nature Medicine
13. JCI - Open-label phase IV trial evaluating nusinersen after onasemnogene abeparvovec in children with spinal muscular atrophy
14. Frontiers | Longitudinal motor function and biomarker correlates in treated adult spinal muscular atrophy: a single-center cohort study
15. Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges - PubMed